- Home
- FFA vs SLN Comparison
FFA vs SLN Comparison
Compare FFA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- SLN
- Stock Information
- Founded
- FFA 2004
- SLN 1994
- Country
- FFA United States
- SLN United Kingdom
- Employees
- FFA N/A
- SLN N/A
- Industry
- FFA Investment Managers
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- SLN Health Care
- Exchange
- FFA Nasdaq
- SLN Nasdaq
- Market Cap
- FFA 416.6M
- SLN 352.2M
- IPO Year
- FFA N/A
- SLN N/A
- Fundamental
- Price
- FFA $20.60
- SLN $6.51
- Analyst Decision
- FFA
- SLN Strong Buy
- Analyst Count
- FFA 0
- SLN 4
- Target Price
- FFA N/A
- SLN $61.50
- AVG Volume (30 Days)
- FFA 26.1K
- SLN 761.1K
- Earning Date
- FFA 01-01-0001
- SLN 11-14-2024
- Dividend Yield
- FFA 6.72%
- SLN N/A
- EPS Growth
- FFA N/A
- SLN N/A
- EPS
- FFA N/A
- SLN N/A
- Revenue
- FFA N/A
- SLN $21,773,221.00
- Revenue This Year
- FFA N/A
- SLN N/A
- Revenue Next Year
- FFA N/A
- SLN $104.98
- P/E Ratio
- FFA N/A
- SLN N/A
- Revenue Growth
- FFA N/A
- SLN N/A
- 52 Week Low
- FFA $15.84
- SLN $5.81
- 52 Week High
- FFA $19.30
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- FFA 50.14
- SLN 27.24
- Support Level
- FFA $20.92
- SLN $6.06
- Resistance Level
- FFA $21.14
- SLN $8.88
- Average True Range (ATR)
- FFA 0.19
- SLN 0.72
- MACD
- FFA -0.04
- SLN 0.22
- Stochastic Oscillator
- FFA 0.00
- SLN 22.52
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.